Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.59 |
| ▸ | MDM4 | O15151 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | TLR2 | O60603 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29470876 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL19402725 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL13402819 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29414971 | 1.00 | MDM2 (0.59) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL29400571 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL12527832 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31614333 | 0.93 | MDM2 (0.53) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL6158363 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL436024 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A | |
| SCHEMBL31681399 | 0.91 | MDM2 (0.57) | MDM2MDM4TP53TLR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743108-A1 | COMPOSITIONS OF PNEUMOCOCCAL ANTIGENS | Virometix AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4720093-A2 | METHODS FOR MAKING PEPTIDE CONJUGATES AND THE PRODUCT MADE THEREFROM | Decoy Therapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260042806-A1 | NOVEL PORE MONOMERS AND PORES | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-02-12 | — | — | US | disclosed |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12441760-B2 | Amino diacids containing peptide modifiers | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-10-14 | — | — | US | disclosed |
| US-20250243255-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | SANOFI (FR) | 2025-07-31 | — | — | US | disclosed |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | disclosed |
| EP-4565275-A1 | NUCLEIC ACID COMPOSITIONS COMPRISING AMPHIPHILIC OLIGO ETHYLENE GLYCOL (OEG)-CONJUGATED COMPOUNDS AND METHODS OF USING SUCH COMPOUNDS AND COMPOSITIONS | BioNTech SE (DE) | 2025-06-11 | — | — | EP | disclosed |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-05-22 | — | — | US | disclosed |
| US-20250064951-A1 | DENDRITIC POLYELECTROLYTE ZWITTERIONS, JANUS-TYPE CONJUGATE COMPRISING SAME AND USES THEREOF | ARTPROBIO CO., LTD. (KR) | 2025-02-27 | — | — | US | disclosed |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-04-06 | — | — | US | disclosed |
| WO-2023031455-A1 | NEW PEPTIDES AS POTENT AND SELECTIVE GIP RECEPTOR AGONISTS | SANOFI SA (FR) | 2023-03-09 | — | — | WO | disclosed |
| EP-4110800-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | SANOFI (FR) | 2023-01-04 | — | — | EP | disclosed |
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | IMMUNOMEDICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4101506-A1 | CONJUGATE BETWEEN ANTIBODY OR PEPTIDE AND PHTHALOCYANINE DYE | The University of Tokyo (JP) | 2022-12-14 | — | — | EP | disclosed |
| US-20220387608-A1 | ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-12-08 | — | — | US | disclosed |
| EP-3912643-B1 | IMMUNOCONJUGATES WITH AN INTRACELLULARLY-CLEAVABLE LINKAGE | IMMUNOMEDICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| EP-4035689-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | Immunomedics Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| EP-2900277-B1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441760-B2 | Amino diacids containing peptide modifiers | PTMS, PEPD, NGLY1 | MDM2 1037/4885MDM4 930/4885TP53 1067/4885 |
| US-20220387608-A1 | ADRENOMEDULLIN-ANALOGUES FOR LONG-TERM STABILIZATION AND THEIR USE | VEGFA, ADM2, SERPINA6 | MDM2 2636/4885MDM4 2096/4885TP53 3647/4885 |
| US-20250163120-A1 | SOLID PHASE PEPTIDE SYNTHESIS OF INSULIN USING SIDE CHAIN ANCHORED LYSINE | IAPP, INSR, INSRR | MDM2 1868/4885MDM4 4329/4885TP53 3076/4885 |
| US-11541047-B2 | Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity | CD74, CD2, CD22 | MDM2 1165/4885MDM4 1582/4885TP53 58/4885 |
| US-20260014140-A1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | CD74, CD2, CD274 | MDM2 1855/4885MDM4 845/4885TP53 43/4885 |
| US-20250243255-A1 | CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY | CRHR2, CRH, CRHR1 | MDM2 4844/4885MDM4 4879/4885TP53 4810/4885 |
| US-20260042806-A1 | NOVEL PORE MONOMERS AND PORES | SCNN1G, CACNG3, ASIC3 | MDM2 4817/4885MDM4 4236/4885TP53 1981/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | MDM2 3251/4885MDM4 4759/4885TP53 3685/4885 |
| US-20230103631-A1 | PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS | GIPR, GLP1R, GPR119 | MDM2 4152/4885MDM4 3928/4885TP53 4324/4885 |
| US-20250064951-A1 | DENDRITIC POLYELECTROLYTE ZWITTERIONS, JANUS-TYPE CONJUGATE COMPRISING SAME AND USES THEREOF | PDCD6, PDCD4, CD2 | MDM2 4467/4885MDM4 2009/4885TP53 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.